Indegene Peer Comparison

NSE: INDGN | BSE: 544172

₹586.80

₹-6.65 (-1.12%)

As on 30-Oct-2026IST

Market cap

₹14,164 Cr

Revenue (TTM)

₹4,131 Cr

P/E Ratio

34.5

P/B Ratio

4.2

Div. Yield

0.4 %

Edit

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Market cap (₹ Cr)	14,164	7,911	547	278	15
Revenue (₹ Cr)	4,131	979	388	145	0
Net Profit (₹ Cr)	411.10	279.70	35.56	-4.90	--
Net Margin (%)	9.78	27.97	8.59	-3.31	-0.79
RoE (%)	13.13	76.43	6.94	-4.53	-0.03
Price to Earnings	34.45	28.28	15.35	--	--
Price-To-Book	4.22	18.64	1.25	2.95	3.73

Income Statement (₹ Cr)

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Operating Revenue	3,510.50	878.40	410.77	128.44	0.84
Total Income	3,582.50	896.80	431.33	131.94	0.85
Total Expenditure	2,891.50	569.40	374.67	131.93	0.40
EBITDA	619.00	309.00	36.11	-3.49	0.44
Depreciation	126.40	11.70	5.30	8.46	0.00
EBIT	492.60	297.30	30.80	-11.95	0.44
Interest	19.30	2.00	5.27	3.33	0.00
Other Income	72.00	18.40	20.56	3.50	0.00
Exceptional Items	-20.30	6.60	1.77	--	--
Profit before Tax	525.00	320.30	48.27	-11.78	0.44
Provision for Tax	123.90	80.20	9.92	-1.34	0.09
Profit after Tax	401.10	240.10	38.36	-10.44	0.36

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Shareholder's Funds	3,138.70	384.00	419.77	92.39	3.90
Minority Interest	--	--	0.00	-1.56	--
Non-Current Liabilities	318.60	229.90	23.22	29.81	0.00
Current Liabilities	1,086.20	128.40	244.03	53.90	0.46
Total Liabilities	4,620.30	750.80	690.89	174.54	4.36

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Non-Current Assets	1,925.10	248.00	127.78	111.26	1.73
Current Assets	2,618.40	494.30	553.60	63.28	2.62
Total Assets	4,620.30	750.80	690.89	174.54	4.36
Total Debt*	0.00	0.00	42.73	48.36	0.00
Net Current Assets	1,532.20	365.90	309.57	9.38	2.16
Contingent Liabilities	--	1.50	45.15	37.44	--

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Cash From Operating Activities	650.80	174.80	0.48	5.24	0.03
Cash Flow from Investing Activities	-512.40	7.60	-112.31	-9.41	0.01
Cash from Financing Activities	-82.60	-134.50	189.66	4.19	--
Net Cash Inflow / Outflow	55.80	47.90	77.83	0.02	0.04

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
ROCE (%)	18.92	98.11	15.51	-5.96	11.87
ROE (%)	14.14	73.20	12.94	-10.64	9.57
ROA (%)	10.31	37.26	6.90	-5.95	8.20
EBIT Margin (%)	19.68	37.27	13.79	0.01	52.63
Net Margin (%)	11.20	26.77	8.89	-7.91	41.97
Cash Profit Margin (%)	15.03	27.35	10.63	-1.54	42.50

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Revenue Growth (%)	23.64	21.24	25.75	-7.26	411.25
EBIT Growth (%)	7.72	15.44	17.94	-99.94	2,529.91
Net Profit Growth (%)	-1.38	32.65	-17.43	-231.54	2,245.51
EPS Growth (%)	-1.79	32.65	-39.83	-225.21	2,245.67
Book Value Growth (%)	19.89	41.18	142.48	-11.84	10.05

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Price / Earnings	26.06	43.36	16.17	0.00	50.26
Price / Book Value	3.38	27.11	1.48	1.74	4.59
Dividend Yield (%)	0.52	1.66	0.43	0.00	0.00
EV/EBITDA	14.57	30.65	8.02	0.00	40.19
Market Cap (₹ Cr)	10,450.76	10,410.62	620.31	159.68	17.90

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Debt to Equity	0.00	0.00	0.10	0.53	0.00
Short term debt to equity ratio	--	--	0.10	0.21	--
Current Ratio	2.41	3.85	2.27	1.17	5.73
Quick Ratio	2.41	3.37	2.18	0.92	5.11
Interest Coverage	28.20	161.15	10.17	-2.54	2,845.31

	Indegene	Sanofi Consumer Healthcare India	Fabtech Technologies	Lyka Labs	Genomic Biotech
Debtors to sales (%)	27.97	3.37	58.80	27.28	262.40
Asset Turnover	0.90	1.43	0.74	0.73	0.19
Receivable days	90.10	8.58	174.27	110.99	1,026.01
Inventory Days	0.00	20.38	35.88	37.08	122.93
Payable days	--	118.89	181.60	115.42	554.30
Cash Conversion Cycle	--	-89.93	28.56	32.64	594.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.